2-氨基-5-溴-4-氯苯甲酸 | 50419-88-0

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-5-溴-4-氯苯甲酸
• 英文名称: 2-amino-5-bromo-4-chlorobenzoic acid
• 英文别名: 5-bromo-4-chloro-2-aminobenzoic acid
• CAS: 50419-88-0
• 化学式: C₇H₅BrClNO₂
• 分子量: 250.479
• InChiKey: TUDNMLBIHIWVJM-UHFFFAOYSA-N

物化性质

• 沸点：
  385.0±42.0 °C(Predicted)
• 密度：
  1.892

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2-8°C，避光、干燥密闭保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Amino-5-bromo-4-chlorobenzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Amino-5-bromo-4-chlorobenzoic acid
CAS number: 50419-88-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5BrClNO2
Molecular weight: 250.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-5-溴-4-氯苯甲酸 在 硫酸 、 sodium nitrite 、 potassium iodide 作用下， 以 二甲基亚砜 、 水 为溶剂， 反应 4.0h， 生成 5-bromo-4-chloro-2-iodobenzoic acid
  参考文献：
  名称：

  Synthesis of DIBAC analogues with excellent SPAAC rate constants

  摘要：

  四种新的DIBAC类似物显示出优秀的SPAAC速率常数，使它们与目前已知最快的环辛烯相媲美。

  DOI：

  10.1039/c4ob00694a
• 作为产物：
  描述：

  N-(5-氯-2-甲基苯基)乙酰胺 在 potassium permanganate 、 水 、 溴 、 magnesium sulfate 、 sodium hydroxide 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 14.5h， 生成 2-氨基-5-溴-4-氯苯甲酸
  参考文献：
  名称：

  吲哚乙酸酯作为吲哚氧基糖苷的方便中间体

  摘要：

  使用可扩展的路线以极好的收率获得了具有不同卤化物取代模式的吲哚酸甲酯和烯丙酯。这些关键中间体的相转移糖基化是用各种糖基卤化物进行的。随后温和的银介导的脱羧作用，然后是 Zemplen 脱乙酰作用，以良好的总产率得到吲哚酚苷。吲哚酚苷是酶筛选和酶活性监测的成熟和广泛使用的工具。过去，它们的合成一直很困难，因此这种新方法导致了各种有用的结构。

  DOI：

  10.1002/ejoc.201301198

文献信息

• [EN] 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES<br/>[FR] 2 -ARYLAMINOQUINAZOLINES DESTINÉES AU TRAITEMENT DES MALADIES PROLIFÉRATIVES
  申请人：NOVARTIS AG

  公开号：WO2009153313A1

  公开（公告）日：2009-12-23

  The invention provides novel compounds that are inhibitors of PDKI. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or composition.

  这项发明提供了一种抑制PDKI的新型化合物。还提供了包括这些化合物的药物组合物，以及使用这些化合物或组合物治疗增殖性疾病，如癌症的方法。
• [EN] INHIBITORS OF KRAS G12C<br/>[FR] INHIBITEURS DE K-RAS G12C
  申请人：ARAXES PHARMA LLC

  公开号：WO2015054572A1

  公开（公告）日：2015-04-16

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了作为G12C突变KRAS蛋白抑制剂活性的化合物。这些化合物具有以下结构（I）：或其药用可接受的盐、互变异构体、前药或立体异构体，其中R1、R2a、R3a、R3b、R4a、R4b、G1、G2、L1、L2、m1、m2、A、B、W、X、Y、Z和E如本文所定义。还提供了与制备和使用这些化合物相关的方法，包括含有这些化合物的药物组合物以及调节G12C突变KRAS蛋白活性以治疗癌症等疾病的方法。
• INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
  申请人：Bifulco, Jr. Neil

  公开号：US20150119405A1

  公开（公告）日：2015-04-30

  Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

  本处描述的是FGFR-4的抑制剂，包括含有此类化合物的药物组合物，以及使用此类化合物和组合物的方法。
• [EN] COMBINATION THERAPIES FOR TREATMENT OF CANCER<br/>[FR] THÉRAPIES COMBINATOIRES POUR LE TRAITEMENT DU CANCER
  申请人：ARAXES PHARMA LLC

  公开号：WO2016044772A1

  公开（公告）日：2016-03-24

  Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

  提供用于治疗与KRAS基因突变相关的癌症的联合疗法。还提供了包含治疗剂的组合物，用于治疗与KRAS基因突变相关的癌症。
• CONDENSED POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT INCLUDING THE SAME
  申请人：Kosuge Tetsuya

  公开号：US20130048965A1

  公开（公告）日：2013-02-28

  A condensed polycyclic compound which emits green light and which has a high chemical stability and an organic light emitting element including the same are provided. A condensed polycyclic compound represented by the general formula [1] or [2] described in claim 1 is provided. In the formula [1] and [2], R 1 to R 10 are independently selected from the group consisting of a hydrogen atom, a straight or branched alkyl group having 1 to 4 carbon atoms, and a substituted or unsubstituted aromatic hydrocarbon group having 6 to 22 carbon atoms.

  提供了一种发射绿光且具有高化学稳定性的缩合多环化合物，以及包括该化合物的有机发光元件。提供了一种由权利要求1中描述的一般式[1]或[2]表示的缩合多环化合物。在式[1]和[2]中，R1到R10独立地选自由氢原子、具有1至4个碳原子的直链或支链烷基基团，以及具有6至22个碳原子的取代或未取代芳香烃基团的群。